Cell No. : Cell Name
RCB2532 : HuO 9N2 (O9N2)
update : 2024/08/14
|
| Comment | Human cell line derived from osteosarcoma. TKG0451 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Fukuda, Hiroshi
|
| Originator |
Kawai, A.
|
| Year of deposit |
2007
|
| Original cell |
TKG0451
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Tissue |
bone
|
| Disease name |
osteosarcoma
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0451）
|
|
Lifespan |
infinite
|
| Morphology |
fibroblast-like
|
| Cellosaurus(Expasy) |
CVCL_2958
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
3
|
| User's Publication |
7
|
| Reference |
|
5194
Itano M, Tsuchiya S, Minegishi N, Fujie H, Minegishi M, Morita S, Yambe T, Ohashi Y, Masuda T, Koike T, et al.
Establishment and characterization of a novel human immature megakaryoblastic leukemia cell line, M-MOK, dependent on fibroblasts for its viability.
Exp Hematol
1995
23(12):1301-9
PubMed ID: 7589286
|
|
5193
Kawai A.
A newly established human osteosarcoma cell line with osteoblastic properties.
Clin Orthop Relat Res
1990
256-67
PubMed ID: 2170070
|
|
5192
Kawai A, Ozaki T, Ikeda S, Oda T, Miyazaki M, Sato J, Taketa K, Inoue H.
Two distinct cell lines derived from a human osteosarcoma.
J Cancer Res Clin Oncol
1989
115(6):531-6
PubMed ID: 2691514
DOI: 10.1007/bf00391353
|
| User's Publication |
|
13409
Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T.
Direct conversion of osteosarcoma to adipocytes by targeting TNIK.
JCI Insight
2021
PubMed ID: 33400690
DOI: 10.1172/jci.insight.137245
|
|
13419
Suzuki S, Yuan H, Hirata-Tsuchiya S, Yoshida K, Sato A, Nemoto E, Shiba H, Yamada S.
DMP-1 promoter-associated antisense strand non-coding RNA, panRNA-DMP-1, physically associates with EGFR to repress EGF-induced squamous cell carcinoma migration.
Mol Cell Biochem
2021
PubMed ID: 33420898
DOI: 10.1007/s11010-020-04046-5
|
|
19258
Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A, Yamada T.
Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma
Mol Cancer Ther
2019
9(3):535-44
PubMed ID: 20159990
DOI: 10.1158/1535-7163.MCT-09-0774
|
|
10919
Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcoma
Integr Mol Med
2016
3: 755-760
DOI: 10.15761/IMM.1000239
|
|
6427
Kobayashi E, Satow R, Ono M, Masuda M, Honda K, Sakuma T, Kawai A, Morioka H, Toyama Y, Yamada T.
MicroRNA expression and functional profiles of osteosarcoma.
Oncology
2014
86(2):94-103
PubMed ID: 24457375
DOI: 10.1159/000357408
|
|
6431
Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M, Furukawa K.
Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.
Cancer Sci
2012
103(9):1656-64
PubMed ID: 22632091
DOI: 10.1111/j.1349-7006.2012.02344.x
|
|
18251
Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA.
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling
Int J Oncol
2011
39(1):73-89
PubMed ID: 21537839
DOI: 10.3892/ijo.2011.1020
|
Back
Top
CELL BANK Website
